XOMA Royalty Corporation (XOMA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at XOMA Royalty Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
52-Week Range
Current price 40.20 $ — 78% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 105.3% passed
- More than 10% revenue growth is expected for the coming year -13.6% failed
- Share count grows by less than 3% a year 16.4% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 48.8% passed
- Gross margin at 40% or higher and without meaningful erosion 94.3% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 1.0 x EBITDA passed
- Operating cash flow covers the profits of the last three years -6 m failed
- Return on capital at 15% or higher, or up versus two years ago 4.8% passed
- Insiders hold at least 10% or are net buyers 2.3% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 3.0% below the current price.
- Consensus
- Sell
- Analyst Ratings
- 4
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.55 | 0.55 – 0.55 | 65 | – | 1 |
| 12/31/2027 | -0.05 | -0.05 – -0.05 | 0 | – | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.17 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.22 | – | 9 | 375.40 | -45.50 | -3 | -3 |
| 2025: Q1 | 0.13 | – | 16 | 967.90 | 14.90 | 2 | 2 |
| 2025: Q2 | 0.39 | -56.90 | 13 | 132.20 | 52.50 | 6 | 6 |
| 2025: Q3 | 0.79 | – | 9 | 29.90 | 150.30 | 0 | 0 |
| 2025: Q4 | 0.35 | – | 1 | -83.60 | 426.20 | -6 | -6 |
| 2026: Q1 | 0.25 | 88.60 | 12 | -22.60 | 36.20 | 6 | 6 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 6 | -62 | -54 | -8.89 | -34 | -47 | 29 |
| 2017 | 53 | 17 | 15 | 1.83 | 3 | 6 | 45 |
| 2018 | 5 | -17 | -13 | -1.59 | -13 | 19 | 64 |
| 2019 | 18 | -4 | -2 | -0.23 | 0 | 44 | 96 |
| 2020 | 29 | 12 | 13 | 1.16 | 10 | 86 | 125 |
| 2021 | 38 | 18 | 16 | 1.30 | 23 | 142 | 167 |
| 2022 | 6 | -17 | -17 | -1.50 | -13 | 124 | 140 |
| 2023 | 5 | -42 | -41 | -3.56 | -18 | 89 | 234 |
| 2024 | 28 | -40 | -14 | -1.18 | -14 | 82 | 221 |
| 2025 | 52 | 11 | 32 | 1.76 | 3 | 104 | 273 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
XOMA Royalty Corporation ist ein Biotech-Royalty-Aggregator in den USA, der Schweiz, dem asiatisch-pazifischen Raum und Australien. Es verfügt über ein Portfolio wirtschaftlicher Rechte an künftigen potenziellen Meilenstein- und Royalty-Zahlungen im Zusammenhang mit kommerziellen Produkten und vorkommerziellen Therapiekandidat…
| Employees | 14 |
|---|---|
| Headquarters | EmeryVille, CA |
| Address | 2200 Powell Street, 94608 EmeryVille, United States |
| Phone | 510 204 7200 |
| Website | xoma.com |
| IPO Date | 5. Apr 1989 |
| ISIN | US98419J2069 |
| Stock Split | 1:20 on 10/18/2016 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Bradley Sitko | Chief Investment Officer | 1981 |
| Jeffrey Trigilio | Chief Financial Officer | 1984 |
| Juliane Snowden | Head of Investor Relations | – |
| Maricel Perea Montano | Chief Legal Officer & Corporate Secretary | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 14. Jul 2026 | Bvf Partners L P/Il | 10% Owner | Other | 772,000 | – | – |
| 14. Jul 2026 | Bvf Partners L P/Il | 10% Owner | Other | 412,000 | – | – |
| 14. Jul 2026 | Bvf Partners L P/Il | 10% Owner | Other | 2,773,545 | – | – |
| 14. Jul 2026 | Bvf Partners L P/Il | 10% Owner | Other | 3,635,758 | – | – |
| 14. Jul 2026 | Montano Maricel Perea | Chief Legal Officer | Other | 65 | – | – |
| 14. Jul 2026 | Montano Maricel Perea | Chief Legal Officer | Other | 42,306 | – | – |
| 14. Jul 2026 | Limber Joseph M | Director | Other | 20,000 | – | – |
| 14. Jul 2026 | Limber Joseph M | Director | Other | 10,000 | – | – |
| 14. Jul 2026 | Limber Joseph M | Director | Other | 9,532 | – | – |
| 14. Jul 2026 | Kosacz Barbara | Director | Other | 6,269 | – | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.